Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 4/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GLB1 | P16278 | 1/20 | 0.33 |
| ▸ | GUSB | P08236 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15315442 | 0.86 | — | — | |
| SCHEMBL14504119 | 0.81 | GLB1 (0.41) | GBA1GAAMGAMGLB1GUSB | |
| SCHEMBL15315425 | 0.81 | GLB1 (0.41) | GBA1GAAMGAMGLB1GUSB | |
| SCHEMBL14505206 | 0.81 | GLB1 (0.41) | GBA1GAAMGAMGLB1GUSB | |
| SCHEMBL15315441 | 0.80 | GAA (0.34) | GBA1GAAMGAMGLB1GUSB | |
| SCHEMBL15317972 | 0.78 | GLB1 (0.36) | GBA1GAAGLB1GUSB | |
| SCHEMBL22446857 | 0.78 | GLB1 (0.36) | GBA1GAAGLB1GUSB | |
| SCHEMBL21195989 | 0.78 | GLB1 (0.36) | GBA1GAAGLB1GUSB | |
| SCHEMBL19903708 | 0.76 | GBA1 (0.33) | GBA1GLB1 | |
| SCHEMBL15133927 | 0.74 | GBA1 (0.50) | GBA1GAAGLB1GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2804861-B1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | GENOSCO (US) | 2018-02-28 | — | — | EP | disclosed |
| US-8871778-B2 | Substituted pyrimidine compounds and their use as SYK inhibitors | GENOSCO (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130274242-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | Genosco Inc. | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274242-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | SYK, BTK, LCK | GBA1 1001/4885GAA 725/4885MGAM 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.